objectives To assess the costs and cost-effectiveness of transitioning from antiretroviral therapy (ART) initiation based on CD4 cell count and WHO clinical staging ('Option A') to universal ART ('Option B+') for all HIV-infected pregnant and breastfeeding women in Swaziland.
Introduction
Option B+, which provides lifelong antiretroviral treatment (ART) for all HIV-positive pregnant and breastfeeding women, was by WHO in 2013 and has been adopted by the majority of Sub-Saharan African countries [1, 2] . Experience with implementation of Option B+ is evolving as most countries have only just transitioned or are transitioning from Option A. Option A provides differentiated treatment based on CD4 cell count and WHO stage; those with a CD4 count ≤350 (≤500 in some countries) receive lifelong ART, while women with >350 receive zidovudine (AZT) prophylaxis while pregnant, singledose nevirapine (NVP) and 7 days of AZT or tenofovir (TDF) and lamivudine (3TC) at delivery and NVP for infants while breastfeeding [3] . Option B+ provides ART (efavirenz (EFV)+3TC or emtricitabine (FTC)+TDF) with 6 weeks of daily NVP for infants.
Evaluation of the cost-effectiveness of Option B+ is insufficient. To date, most research on the cost-effectiveness of the Option B+ approach has been assessed through economic modelling [4, 5] . In a review of published literature measuring outcomes relating to infant and maternal outcomes [6] , varied cost-effectiveness results were noted in the data from African countries, with models running from 10 years to a lifetime span, which would incorporate future pregnancies. Due to differences in assumptions, input costs and effects within models the conclusion on cost-effectiveness was not consistent. The most comprehensive of the studies found Option B+ to be cost-effective in terms of infant and partner infections averted [7] . However, there may have been partiality towards Option B+, and there is a clear need for ongoing cost-and cost-effectiveness data on universal ART strategies, including Option B+, in low-to middle-income countries (LMICs).
Limited experience in the utilisation of Option B+ at the time necessitated research into implementation of the approach, as well as recommendations regarding its costeffectiveness. Empirical information on the costs of PMTCT services is important to better utilise resources, for future modelling and to assess the impact of alternative approaches [8] . The aim of this research was to estimate and compare the costs and cost-effectiveness of Option B+ versus Option A in Swaziland.
Methods
The Safe Generations (SG) Study (ClinicalTrials.gov identifier: NCT01891799) was an implementation science research study, designed to evaluate the Option B+ approach to PMTCT. The Swaziland Ministry of Health (MoH) supported the SG Study because among others, cost and cost-effectiveness data were critical in informing Option B+ roll-out costing and planning. The primary outcome for the evaluation was maternal retention in care, defined as the proportion of women with any clinic attendance documented within 56 days of delivery or estimated due date (antenatal retention) and clinic attendance documented within 84 days of 6-months postpartum (postnatal retention). These definitions were based on 1 month after the longest possible ART-dispensing interval during the antenatal and postnatal periods (1 and 2 months, respectively). One of the secondary objectives was to compare the cost-effectiveness of Option A and B+. Other outcomes included the proportion of women initiating antiretroviral medications during pregnancy, time from first antenatal care visit (ANC) to ART initiation, and the proportions of infants testing HIVpositive. The step wedge design allowed comparison between Option A (the standard of care when the study started) and B+, as transition occurred. There was 1 month of transition between Option A and B+ for each clinic. A 26% increase in maternal retention was demonstrated after the transition to Option B+. During the study, 54% of infants were traced and 53% received a Polymerase Chain Reaction (PCR) test. We therefore decided to focus cost-effectiveness analyses on maternal retention and exclude effectiveness outcomes for infants as they may not be representative of the entire study cohort (SG Manuscript under review; [9] ).
Study design
The economic evaluation was retrospectively undertaken from a health services perspective. The cost estimates include both the financial and economic costs. The economic costs differ from the financial costs, as they include training and training materials that were provided through the main study. A full rather than an incremental costing was undertaken.
Study facilities
Five clinics providing PMTCT, HIV care and ART and baby wellness services (among others) were purposively chosen to encompass various factors, which could describe variation in characteristics between health facilities (see Appendix S1). The clinics were visited by a health economist to observe clinic process, measure clinic space, inventory equipment and furniture and assist staff in completing time sheets at three points in time; once while still under Option A, and twice after transition to Option B+. This method was used to assess changes in resource use and staff time, and to familiarise the health economist with the context and study setting.
Costing
Using an ingredients-based approach, the overall clinic costs and the total costs of providing PMTCT services under Option A and B+ were assessed from August 2013 to October 2015. All costs are presented in 2015 United States Dollars (US $). Costs collected in other years were inflated to 2015 US $ using the consumer price index [10, 11] . Costs that were collected in Swazi Lilangeni (SZL) have been converted to US $ using the average exchange rate over the period January 2015 to December 2015 of 12.77 SZL for 1 US $ [12] . The cost per woman receiving prophylaxis per month includes capital costs and recurrent costs.
Capital costs
Equipment and furniture were audited and costed based on current replacement value sourced through medical, hospital equipment and furniture suppliers in South Africa. Building space was costed using current replacement value sourced from Council for Scientific and Industrial Research (CSIR) in South Africa. For logistical and resource reasons we used South African prices.
Start-up costs comprised study-specific training for Option B+ per clinic and toolkits for each clinic. The toolkit is a desktop flipchart, which aids the staff when educating the patients about how to take their medication correctly. Initial costs for training at the clinics are presented separately from the start-up costs. Study records provided the cost of developing, updating and printing the toolkit. Study-specific and initial training included the cost of the venue used, catering, the facilitators' time and any transport provided. Data on initial training on PMTCT under Option A was collected through discussion with the staff providing PMTCT services.
These capital costs were annualised using a discount rate of 3%, with the assumption that the useful lifespan will be 30 years for buildings, 10 years for equipment and furniture, and 5 years each for the toolkit, initial and study-specific training.
Recurrent costs
Salaries of staff at the clinics were obtained from human resources and finance departments in the MoH, non-government organisation (NGO) and a faith-based organisation (FBO) that run the respective clinics. The overhead costs of running and maintaining the clinics were estimated using the expenditure reports from the same finance departments.
The prices of medication were collected from Central Medical Stores Swaziland. The cost per month of medication was calculated by multiplying the price of one pill of the respective medication (taken daily) for ART and cotrimoxazole (CTX) and the price of two pills of AZT (taken daily) by 30 days. All women were given daily CTX (under Option A and B+). If a woman made a visit to the clinic it was assumed that she had received 1 month's worth of medication.
The prices of diagnostic tests (CD4, point of care PIMA CD4, haemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and rapid HIV tests) were obtained from the National Health Laboratory Services South Africa. The cost of receiving the tests at first visit, 6 and 12 months later, was distributed over the time in care, 15 months (the gestation period (9 months) plus 6 months postpartum) to give a per-month diagnostic test cost (per guideline).
Cost allocation
Two unit costs were estimated, a 'cost per visit' and a 'cost per woman treated per month'. The total cost of providing Option A and B+ services was divided by the number of PMTCT visits made in the same period to get the unit 'cost per visit', which does not include diagnostic tests or medication costs.
A 'cost per woman treated per month' was calculated separately for those on AZT and ART under Option A and Option B+, respectively. This was performed by adding the 'cost per visit' to the monthly medication cost and the monthly diagnostic tests cost (which were the same for Option A and B+).
The weighted average cost per woman treated was estimated by multiplying the 'cost per woman treated per month' by the average number of visits made under the two different approaches, respectively, until 6 months postpartum (4.34 for Option A and 4.52 for B+). For Option A and B+, the proportion of those on ART in the study, (36% in Option A and 94% in Option B+) and AZT (64% in Option A and 6% of women who did not initiate ART under the B+ and received AZT) was used to weight the costs, respectively. In addition, the total costs were estimated by multiplying the total number of women enrolled in the study under Option A and B+, respectively, by the weighted average cost per women for Option A and Option B+, respectively.
Cost-effectiveness
Using the weighted average cost per woman treated for each approach, and the effectiveness data from the trialthe maternal loss to follow-up at 6 months postpartumthe incremental cost-effectiveness between the two approaches was estimated. The incremental cost-effectiveness ratios estimated reflect 'the additional cost per mother retained at 6 months postpartum'. These estimates are based on incremental costs and effects from Option A to B+, where Option A is the baseline.
Sensitivity analysis
To assess the uncertainty in the analysis, five univariate sensitivity analyses were performed. Firstly, as Swaziland was rolling out routine viral load monitoring in the poststudy period, the cost of viral load testing was obtained from Swaziland Health Laboratory Services and was added to the primary analysis costs to assess the cost impact of adding viral load testing, to the Option B+ approach, as a monitoring test after 6 months and twelve months on treatment, respectively.
Secondly, TDF + FTC + EFV was donated to the study at a cost to the donor (Merck & Co). The cost of donated TDF + FTC + EFV was collected through study records and was used to assess the cost impact of using this medication on the ICER, rather than the less expensive generic medication (TDF + 3TC + EFV) under the Option B+ approach.
Thirdly, the effectiveness measure of maternal retention was varied by 15% above and below the proportion used in the primary analysis to consider the effect on the ICER. Fourthly, as Option B+ reduces the need for diagnostic testing, the impact of removing all diagnostic tests from the Option B+ approach was assessed.
Lastly, as less intensive training for transition to Option B+ may be provided in the future, the training cost under the primary analysis was reduced to one-third in the sensitivity analysis. This reduction was based on an interview with MoH around training they performed for transition. AAAL0661) . Throughout the study, anonymity of the women has been maintained using unique identifying numbers. Clinic sites have not been mentioned by name. The clinic personnel who filled in timesheets consented verbally, and remain anonymous. Study data were stored on password-protected computers. There were no direct benefits to those participants taking part in the study; however, their participation may positively impact on others who may receive evidencebased PMTCT services in the future.
Ethical considerations

Results
Costs
Using medical record review, under Option A 1296 women (55%) were observed, while 1051 women (45%) were observed under Option B+. Of those, 353 (27%) were retained under Option A and 559 women (53%) were retained under Option B+ (see Table 2 ). A total of 3495 visits (ranging from 364 to 1218) were made under Option A and 2670 visits (ranging between 89 and 1518) were made under Option B+ for the five facilities.
The average cost per clinic visit under Option A was US $113.46 and US $169.65 under Option B+ (see Figure 1) . The cost of medication per month was US $2.26 if a woman was on AZT (US $2.03) and CTX (US $0.23) and US $11.54 if a woman was taking TDF + 3TC + EFV (US $11.31) and CTX (US $0.23) ( Table 1 The weighted average cost per woman treated under Option A was US $525 compared to US $826 under Option B+. The main cost drivers were the start-up costs (study specific training for Option B+ per clinic and toolkits for each clinic), increased training and staff time spent on PMTCT tasks under Option B+ (Figure 1) . Staff time relates to the MoH, NGO and FBO time staff spent on PMTCT tasks under Option A and B+ (separately), with time apportioned through timesheets as described above, which has been costed using the graded salaries as provided by the three organisations (MoH, NGO and FBO).
For the five sites, the total cost for PMTCT during the study period was US $868,426 under Option B+ and US $680 508 under Option A. The difference in cost between the two approaches was US $187 918 (Table 2) . Considering the 26% difference in maternal retention between the two approaches in favour of Option B+, the incremental cost-effectiveness ratio was estimated at US $912 (see Table 2 ).
Sensitivity analysis
Findings were sensitive to viral load testing, removing all tests, reduced training, medications and retention rates. Introducing viral load testing at 6 and 12 months after initial visits, using more expensive medication or decreasing the maternal retention under Option B+ increased the ICER, thereby reducing the approach's cost-effectiveness. Removing all diagnostic testing, increasing maternal retention and reducing the intensity of training under Option B+ decreased the ICER and made Option B+ more cost-effective (Table 3) .
Discussion
The cost and cost-effectiveness outcomes from this study indicate that there is a robust economic case for pursuing the Option B+ approach in Swaziland and similar settings such as South Africa. This is one of the first studies to present an empirical economic evaluation using primary patient level data as opposed to modelled data as has been done in the recent past [7, [13] [14] [15] [16] [17] [18] [19] [20] .
Option B+ is a costlier, but also a more effective approach in terms of maternal retention. The incremental cost-effectiveness ratio was US $912. This means that, under the Option B+ approach, it costs US $912 for every additional mother retained to 6 months postpartum. This is well below Swaziland's 2015 per capita gross domestic profit (GDP) of US $3068 [21] , and falls within the cost-effective range for the country (US $288-US $1559) [22] , which suggests that Option B+ is highly cost-effective in this setting.
In this study, personnel costs were the key cost driver, which is similar to other studies [8, 23] , and can be attributed to the increased staff time spent on PMTCT tasks under Option B+. Start-up costs and increased training provided under Option B+ also impacted on the cost of the Option B+ programme.
Consistent cost results were found in this study to that of Zulliger et al. [24] , who explored the cost-effectiveness of accelerating the initiation of ART among pregnant women, finding it cost US $880 per women for 1 year, compared to standard of care, which cost US $220. This is similar to the weighted average cost per woman treated under Option B+ in this study of US $826, and may be comparable as the settings are alike and the costs were empirically collected.
Divergent results were found between this study, where weighted average cost per woman treated under the Option A approach was US $525 (and US $826 under Option B+), and the higher estimates in empirical work by Bautista-Arredondo et al. [8] . They estimated the costs per woman under the Option A approach receiving medication in Kenya, South Africa and Zambia as ranging from US $704 to US $1385 (in 2013 US $), while in Rwanda the cost of Option B+ was estimated to be US $2214 per woman [8] .
Results from Malawi [18] , Rwanda [25] and Cameroon [26] differ from our study findings as they modelled estimates, are from settings other than Swaziland and have differing time horizons. In the five papers reviewed by Karnon and Orji, cost inputs in the models for Option A ranged from US $16 to 76, while costs for Option B+ varied from US $114 to 470 per year [6] , which are lower than our estimates. In this study, the total cost for PMTCT in the five sites during the study period was US $680 508 under Option A and US $868 426 under Option B+. In comparison, the total programme costs for Option B+ as simulated by Tweya et al., [18] in Malawi were US $431 910 for a first pregnancy and US $662 074 for a woman's second pregnancy.
The intermediate outcome of retention in care is an important aspect in the continuum of HIV care as being diagnosed and starting ART are vulnerable areas of the HIV programme [27] . Retention in care is an important precursor to a final outcome of prevention of mother-tochild transmission of HIV, as retention increases the potential time of patients being in care and on treatment. Improved retention could also be linked to increased staff training, improved staff skills and the increased patientprovider time. Hence providing additional staff training on PMTCT may result in higher retention rates. Attention needs to be paid to continuing the support and training of healthcare workers so that retention can be maintained and improved [28] . In Cameroon (Option B+), retention rates of 88% were noted at 6 months, with decreases in retention over time [26] which are much higher than the retention rates found in this study.
Under the Option B+ approach, more women were placed on ART, requiring more follow-up and more time with providers. However, no major changes in infrastructure or staffing structure were needed to implement Option B+. This could speak to an increase in efficiency, and use of spare capacity, which may not be available in all settings. Once Option B+ is established and with scale, we may find that costs stabilise and plateau at a level that is lower than those found in this study [29] .
There is a shift towards universal lifelong access to ART for all individuals with HIV (a test and treat strategy, not just pregnant women) regardless of their CD4 count (Joint United Nations Programme on HIV/AIDS (UNAIDS), [30, 31] . Assessing the impact of Option B+ for pregnant women with HIV will help policymakers highlight areas that need to be addressed as general access to ART improves and more individuals are placed on ART. Even with the introduction of Option B+, the rate of retention was still suboptimal, which emphasises that focus needs to be placed on improving and maintaining retention. Better retention rates may put additional stress on the health system as there would be more women on ART. The unit costs in this study could be used to inform a budget for universal lifelong access to ART for all individuals with HIV, taking into consideration that there may be slight differences in the population group. A transition to universal lifelong treatment would impact on the budget due to scale up of services, as there would not be a differentiation by CD4 count and treatment would be maintained throughout the life of the individual. In addition, other strategies such as community-based approaches may be helpful in supporting those on universal lifelong treatment [32, 33] . 
Limitations
There are several study limitations. The cost of running the Option B+ approach over a longer period was not estimated. Personnel may behave differently due to the nature of being involved in a study, which may impact on both the resources used (i.e. costs) and the effectiveness of the intervention (i.e. retention). Difficulties in infant tracing meant that mother-to-child transmission of HIV was not included as an effectiveness measure and cost-effectiveness outcome. Future studies should be aware of the challenges of tracing these infants, ensuring that medical file numbers and other linkages are maintained. In this analysis, we have not considered how the presumed health benefits of mothers being on ART and the loss to follow-up of patients may impact on the overall estimation of the cost-effectiveness. Due to the nature of the step wedge design, health economic researchers did not collect data at the same post-transition time points for all clinics. This may mean some variability in the information collected in timesheets over time. There is currently no willingness to pay (WTP) threshold for Swaziland and therefore GDP per capita and the costeffective range for Swaziland were used as thresholds. This limits comparability with studies in countries with WTP thresholds. In addition, dolutegravir-based regimens are expected to be introduced more widely and updated estimates of cost and cost-effectiveness will be needed. Finally, there is a limit to the generalisability of the results as the data was collected specifically in the context of Swaziland transitioning from Option A to Option B+. However, in settings such as South Africa, where there is no empirical evidence regarding cost-effectiveness of Option B+, this study may help inform decision making.
Conclusions
Overall, findings from this economic evaluation suggest that there is a strong economic case for pursuing the Option B+ approach in Swaziland. Increased staff time and providing additional staff training as was the case in this study, may result in higher retention rates in other settings, which in turn may positively impact on the health of women in such programmes. As universal HIV treatment programmes are implemented, providing Option B+ for women who are pregnant and HIV-positive is a good platform for initiating this expansion. Cost findings from this study could inform budgeting for countries moving to the test and treat strategy for all individuals living with HIV. Based on this study, there may be optimistic implications in terms of retention to care as all those individuals with HIV are offered lifelong treatment. 
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